Phio Pharmaceuticals Corp (PHIO)

[Inoviorulez]

Just to add one more thing from the CEO of RXII in interview Excaliard (spinoff of ISIS acquired by Pfizer) reported positive results in their phase 1 trial of 30% to 40% reduction of scarring and they used higher dosing.

RXII achieved higher than excaliard drug at 42%, but RXII used a lower dose regimen than Excaliard. Take note of that RXII got better reduction of scarring with a lower dose than Excaliards drug. Meaning with the additional cohorts added to multi dose RXII's phase 1 drug will go way higher than Excaliards phase 1.

Also don't count out the reverse split I'm sure the CEO did it for a reason. Their was probably high demand for institutions to buy in after symposium, but they can't when the stock trades for .15 cents. Now at this price and an uplisting to Nasdaq lots of institutions can start building a position.